One trial of Pfizer’s drug in early breast cancer has been stopped, and expectations dim for another.
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
Five months after Novartis paid $9.7bn for the RNAi project’s maker, Blackstone has put down a $1bn bet on a partial royalty interest.
US drug stocks were shielded from bigger falls in the first quarter by leading coronavirus researchers, leaving groups listed in Japan and Europe to tumble harder.
The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.